ICT Priorities in Pharmaceuticals - Enterprise ICT investment plans
This report presents the findings from a survey of 102 pharmaceutical regarding their Information & Communications Technology (ICT) investment priorities. The survey investigates the core technologies which pharmaceutical companies are investing in, including the likes of enterprise applications, security, mobility, communications & collaboration, and Cloud Computing.
Introduction and Landscape
Why was the report written?
In order to provide deeper insights into pharmaceutical companies’ ICT investment priorities and strategic objectives.
What is the current market landscape and what is changing?
Kable’s survey finds that apart from investing in core technologies (such as security, enterprise applications, and IT systems management), many pharmaceutical companies are looking to adopt green IT and virtualization, cloud computing, mobility, and business intelligence solutions.
What are the key drivers behind recent market changes?
Demand for such advanced technologies are increasing amongst pharmaceutical companies as these solutions will help them to reduce their costs, enhance operational efficiencies, achieve sustainability, and improve customer experience.
What makes this report unique and essential to read?
Kable Global ICT Intelligence has invested significant resources in order to interview CIOs and IT managers about their IT investment priorities. Very few IT analyst houses will have interviewed 100+ ICT decision makers in pharmaceutical industry in H2 2012.
Key Features and Benefits
Recognize pharmaceutical companies’ strategic objectives with regards to their ICT investments.
Identify pharmaceutical companies’ investment priorities based on their budget allocations across core technology categories such as enterprise applications, security, mobility, communications & collaboration, and Cloud Computing, etc.
Learn about the drivers that are influencing pharmaceutical companies’ investments in each technology category.
Establish how pharmaceutical companies’ IT budgets are currently allocated across various segments within a technology category.
Gain insight into how pharmaceutical companies’ plan to change their ICT budget allocations across various segments within a technology category.
Key Market Issues
The demand for security solutions is set to continue, with 87% of survey respondents planning investments in this area in the next two years, owing to the increasing adoption of enterprise mobility and rising data security threats in pharmaceutical companies.
Companies in the pharmaceutical sector are keen to deploy a cost effective supply chain solution in order to streamline their operations.
In order to curb the impact of competition and regulatory changes pharmaceuticals companies are looking to adopt various predictive analytics and modelling tools in order to make smarter business decisions by understanding the latest market trends and customer preferences.
Managing and monitoring the ever increasing volumes of information across a global organisation is a complex task, which is driving the adoption of various enterprise content management (ECM) solutions.
The increasing complexity of enterprise ICT infrastructure is consequently driving the demand for IT systems management to manage ICT assets effectively and keep them running efficiently, while at the same time removing any redundancies and wastage of resources.
With 60% of respondents planning investments in this solution through to the end of 2014, the demand for PLM solutions is set to gain momentum in the coming months.
Kable’s survey finds that social sentiment analysis is set to receive increasing investments, as 53% of pharmaceutical companies are planning to invest in this technology through to the end of 2014.
The demand for tablet computing is set to increase in the near future, with 53% of pharmaceutical companies planning to invest here through to the end of 2014.
Web/video conferencing and IP-contact centres occupy the top two positions on survey respondents’ priority lists. While web/video conferencing has a penetration rate of 65% among pharmaceutical companies, 63% already operate IP-contact centres.
Kable expects high levels of investment in hybrid clouds in the near future, as an increasing number of pharmaceutical companies are planning to make investments in these solutions through to the end of 2014.